Co-Diagnostics (CODX) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was $0.1 million, down from $0.5 million in Q1 2024, mainly due to lower product and grant revenues and timing of grant revenue recognition.

• Net loss narrowed to $7.5 million from $9.3 million year-over-year, with a loss per share of $0.24 versus $0.31, mainly from reduced sales, marketing, and R&D expenses.

• Operating expenses decreased to $8.6 million from $10.5 million year-over-year.

• The company continues to develop its CODEX PCR platform and test pipeline, targeting clinical evaluations for TB, COVID-19, respiratory, and HPV panels, with regulatory submissions ongoing.

• Cash, cash equivalents, and marketable securities totaled $21.5 million as of March 31, 2025.

Financial highlights

• Product revenue was $50,277 in Q1 2025, compared to $252,745 in Q1 2024; no grant revenue recognized in Q1 2025.

• Gross profit was $28,687 in Q1 2025, down from $233,349 in Q1 2024.

• Adjusted EBITDA loss improved to $7.4 million from $8.4 million year-over-year.

• Net cash used in operating activities was $8.7 million, slightly higher than $8.5 million in Q1 2024.

• Basic and diluted loss per share was $(0.24), compared to $(0.31) in Q1 2024.

Outlook and guidance

• Clinical trials for COVID-19, TB, HPV, and respiratory panels expected to commence in 2025, with manufacturing facility completion in India by year-end.

• Regulatory submissions planned for India, South Africa, and the US, with initial focus on India.

• Commercial launch timing dependent on disease prevalence and clinical trial progress.

• Management anticipates continued operating losses and cash use in the near term, with additional financing likely needed.

• Continued focus on cost management and operational efficiency.